Generic Name and Formulations:
Antihemophilic Factor VIII:C (human) 250 IU, 500IU, 1000 IU, 1500 IU; per vial; lyophilized concentrate for IV infusion after reconstitution; contains albumin.
CSL Behring, LLC
Indications for MONOCLATE-P:
Treatment and surgical prophylaxis for Hemophilia A.
Adults and Children:
Dosage Required (IU) = Body Weight (kg) × Desired % Factor VIII Increase × 0.5. Individualize. Infusion rate: 2mL/min if tolerated. Mild hemorrhages: single infusion to attain 30% FVIII increase. Moderate hemorrhage or minor surgery: initially 15–25 IU/kg, then 10–15 IU/kg every 8–12hrs if needed. Severe hemorrhage: initially 40–50 IU/kg, then 20–25 IU/kg every 8–12hrs. Major surgery: give first dose 1 hour pre-op to attain 80–100% FVIII increase, then give a ½ dose 5 hours after first dose; maintain daily at ≥30% FVIII increase for 10–14 days post-op.
Mouse protein sensitivity.
Not for von Willebrand's disease. Confirm Factor VIII deficiency prior to treatment. Contains human plasma; monitor for possible infection transmission. Large or frequent dosing: monitor hematocrit for signs of progressive anemia. Monitor for development of Factor VIII inhibitors. Pregnancy (Cat.C).
Allergic reactions, chills, GI upset, inj site reactions, antibody formation.
Report any infections suspected to be transmitted by Monoclate-P to (800) 504-5434.
Single-dose vial—1 (w. diluent, supplies)
Clinical Pain Advisor Articles
- Analyzing Coverage of Nonpharmacologic Treatments for Low Back Pain
- Smartphone App Helps Evaluate Catastrophizing in Chronic Pain
- Predicting the Magnitude of Placebo Analgesia in Chronic Pain
- Dsuvia Gains FDA Approval: We Want to Hear Your Thoughts
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Seven-Item Pain Intensity Measure Reliable in Individuals With Dementia
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Dozens of Medical Groups Join Forces to Improve Diagnoses
- FDA Grants Non-Opioid Analgesic VVZ-149 Fast Track Status
- Little to No Association Found Between Physician Performance and Medical School Ranking